Stay updated with breaking news from Therapeutic Vector Evolution. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Injection-free subgroup results demonstrated that a single intravitreal dose of 4D-150 without any supplemental anti-VEGF injections resulted in stable mean visual acuity that was equal to or higher than in
Preclinical data for 4D-175 for geographic atrophy to be presented in an oral presentation4D-150 PRISM randomized Phase 2 Dose Expansion Cohort 24-week encore results to be presented in a poster ...
EMERYVILLE, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a leading clinical-stage genetic medicines company...
51 wet AMD patients with severe disease activity and high treatment burden were randomized to high or low dose 4D-150 or aflibercept control regimen4D-150 was well tolerated with a favorable...
51 wet AMD patients with severe disease activity (mean of 442 µm central subfield thickness & presence of retinal fluid) and high treatment burden...